StocksInsight

IVZ Stock vs the S&P 500: Returns, Risk and Crash History

Invesco Ltd., financial services (market value $12.5 billion), an S&P 500 member: how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Returns to Oct 30, 2026; analyst data as of Nov 16, 2026.

Published Updated 4 min readHow we research

What changed since Nov 9

Exent re-checks this page every day. Ratings appear 30 days after they are published; the top‑ranked analysts’ calls are not counted here, they are in Gems.

+5 new ratings38% Buy ratings (was 42%)

Key takeaways

  • IVZ returned +34.9% over the 5 years to Oct 30, 2026 versus +75.9% for the S&P 500: it lagged the index.
  • Its 5-year Sharpe ratio was 0.24 against 0.58 for the S&P 500.
  • Its deepest crisis drawdown was −85.3% in the global financial crisis (2007–09) (S&P 500: −56.5%).
  • Five‑year volatility was 36.4% and beta 1.69.
  • 14 analysts rated it in the past year; 38% of their latest calls were Buy.
  • IVZ beat earnings estimates in 8 of its last 12 reports; the stock moved 4.6% on average, up or down, around each report.

What do the best‑ranked analysts on IVZ say now? See it in Exent Gems →

Did IVZ beat the S&P 500?

Over the 5 years to Oct 30, 2026, Invesco Ltd. (IVZ) returned +34.9% including dividends, versus +75.9% for the S&P 500 (SPY). It lagged the index by 41.0 percentage points, or +6.2% a year against +12.0%.

PeriodIVZS&P 500IVZ per yearS&P 500 per yearResult
1 year+20.8%+12.0%+20.8%+12.0%Beat
3 years+144.0%+87.4%+34.6%+23.3%Beat
5 years+34.9%+75.9%+6.2%+12.0%Lagged
10 years+55.4%+316.3%+4.5%+15.3%Lagged
  • 1 year
    IVZ
    +20.8%
    S&P 500
    +12.0%
    IVZ per year
    +20.8%
    S&P 500 per year
    +12.0%
    Result
    Beat
  • 3 years
    IVZ
    +144.0%
    S&P 500
    +87.4%
    IVZ per year
    +34.6%
    S&P 500 per year
    +23.3%
    Result
    Beat
  • 5 years
    IVZ
    +34.9%
    S&P 500
    +75.9%
    IVZ per year
    +6.2%
    S&P 500 per year
    +12.0%
    Result
    Lagged
  • 10 years
    IVZ
    +55.4%
    S&P 500
    +316.3%
    IVZ per year
    +4.5%
    S&P 500 per year
    +15.3%
    Result
    Lagged

Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also how to beat the S&P 500.

IVZ is in the S&P 500 (members as of Oct 20, 2026); the list shows every member’s return against the index.

What Wall Street analysts say about IVZ

In the 12 months to 30 days ago, 14 analysts published 194 ratings on IVZ. Their latest calls were 38% Buy, 62% Hold and 0% Sell. 9 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.

The consensus 12‑month price target was $34.57 (range $31.00–$39.00), +20.7% from the last price. Remember that the average analyst’s target is hit only about half the time: how accurate are price targets?

Top‑ranked analyst coveringFirmStarsPrice‑target hit rate
??????5.0★65.0%
Brian BedellDeutsche Bank 4.9★55.3%
Stephen BiggarArgus Research4.9★53.5%
Kenneth LeeRBC Capital4.8★28.4%
Craig SiegenthalerBank of America Securities4.8★53.2%

Other analysts covering IVZ: Glenn Schorr · William Katz

Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on IVZ are, their live calls and the median target of only the top‑rated analysts are in Exent Gems.

The average analyst’s target is reached about 53.0% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. Unlock the top 50 analysts.

IVZ returns by year vs the S&P 500

IVZ beat the S&P 500 in 3 of the 9 full calendar years shown.

YearIVZS&P 500Difference
2026 (to Oct 30, 2026)+8.1%+11.7%−3.6%
2025+57.0%+17.7%+39.3%
2024+3.0%+24.9%−21.9%
2023+4.2%+26.2%−22.0%
2022−18.7%−18.2%−0.5%
2021+36.0%+28.7%+7.3%
2020+3.1%+18.3%−15.2%
2019+14.9%+31.2%−16.3%
2018−52.0%−4.6%−47.4%
2017+24.7%+21.7%+3.0%

IVZ risk-adjusted returns: Sharpe, Sortino and volatility

Over 5 years, IVZ had a Sharpe ratio of 0.24 against 0.58 for the S&P 500, so it earned less return per unit of risk than the index. Its annualized volatility was 37.9% and its beta 1.69: it tended to move about 1.7× as much as the market.

MetricIVZS&P 500
Annual return+6.2%+12.0%
Volatility (annualized)37.9%15.5%
Sharpe ratio0.240.58
Sortino ratio0.390.91
Max drawdown (month-end)−44.7%−23.9%
Beta to the S&P 5001.691.00

Sharpe divides return above cash by total volatility; Sortino counts only downside volatility. Both use monthly returns and the 1–3 month T‑bill ETF (BIL) as the risk‑free rate.

How IVZ behaved in past crashes

IVZ’s deepest fall in the crises below was −85.3% in the global financial crisis (2007–09), against −56.5% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.

CrisisIVZS&P 500Loss on $100,000
Global financial crisis (2007–09)−85.3%−56.5%−$85,300
2018 trade-war selloff−35.6%−20.2%−$35,640
COVID crash (Feb–Mar 2020)−57.8%−34.1%−$57,790
2022 inflation bear market−45.0%−25.4%−$44,960
2025 tariff selloff−33.3%−19.0%−$33,260
WindowIVZ max drawdown
Last 1 year−22.0%
Last 3 years−36.6%
Last 5 years−53.4%
Last 10 years−82.6%

Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the crash test.

What moves with IVZ, and what doesn’t

Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, IVZ’s correlation with the S&P 500 was 0.69, with the Nasdaq‑100 0.51, with long Treasuries (TLT) 0.43 and with gold (GLD) 0.22.

Adding a 5% IVZ position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 16.1%.

Least correlated large capsCorrelationMost correlated large capsCorrelation
LLY−0.05BLK0.73
CRWD−0.04MS0.72
PGR−0.03BNY0.71
ELV0.02GS0.69
MCK0.02BX0.63

Holdings that are highly correlated behave like one position in a selloff. See how to find hidden overlap.

Latest IVZ upgrades, downgrades and price‑target changes

DateRating and targetAnalyst
Nov 11Target cut
Hold
Target $33, was $34
Glenn Schorr
Evercore ISI
Nov 2Target raised
Hold
Target $37, was $34
Craig Siegenthaler
Bank of America Securities
Oct 28Target raised
Hold
Target $33, was $32
Benjamin Budish
Barclays
Oct 14Target cut
Hold
Target $34, was $37
Craig Siegenthaler
Bank of America Securities
Oct 12Target cut
Buy
Target $38, was $39
William Katz
TD Cowen
Oct 12Target raised
Buy
Target $36, was $34
Brennan Hawken
BMO Capital
Oct 9Target raised
Buy
Target $36, was $35
Kenneth Lee
RBC Capital
Oct 9Target cut
Hold
Target $34, was $37
Glenn Schorr
Evercore ISI
Oct 7Target cut
Buy
Target $38, was $39
Alex Bond
KBW
Oct 6Upgrade
Buy
Target $41
Michael Brown
UBS
Oct 5Target cut
Hold
Target $37, was $38
Craig Siegenthaler
Bank of America Securities
Sep 25Target raised
Hold
Target $31, was $30
Michael Cyprys
Morgan Stanley

Named analysts’ rating and price‑target changes on IVZ in the 5 weeks to Oct 20, 2026, shown 30 days after publication (the free analysts’ calls 3 days after). The top‑ranked analysts’ calls are in Exent Gems. See all of the latest analyst upgrades and downgrades.

Do analysts get IVZ right?

Of the 438 analyst price targets on IVZ set from 2019 until a year ago, 69.4% were reached within 12 months (data to Oct 20, 2026), 0.8 points above the 68.6% hit rate of the median stock in Exent’s study of 794 stocks. Targets that were reached took a median of 35 days. The median target sat 7.7% above the share price on the day it was set.

Where analysts said IVZ would be by now: a year ago, 8 analysts had a price target on IVZ, and the median of their latest targets was $26.75. On Oct 20, 2026 IVZ closed at $28.77, 7.5% above it.

69.4%of targets reached within 12 monthsMedian stock: 68.6%
35 daysmedian time to reach a target
+7.5%price now vs the median target set a year ago
AfterCallsMove on the call3 months vs S&P 500
Upgrades of IVZ12+3.7%+9.2%
Upgrades, all stocks11,514+2.5%+3.4%
Downgrades of IVZ12−0.6%−6.2%
Downgrades, all stocks10,700−3.0%−1.6%

The move on the call runs from the close before the rating change to the close after it; the last column is the stock’s return minus the S&P 500’s over the next three months. Averages of rating changes on IVZ through Sep 15, 2026; analysts are not named here. Do analyst upgrades move stocks?

How IVZ moves after earnings

IVZ beat the consensus earnings‑per‑share estimate in 8 of its last 12 quarterly reports, through the one on Jul 28, 2026, and the revenue estimate in 7 of 12. From the close before each report to the close after it, the stock moved 4.6% on average, up or down, against 6.8% for the average report across the 1,002 US stocks Exent tracks. It rose after 7 of the 12 reports. In 4 of the 8 beats the stock still fell.

8/12earnings beats
±4.6%average move per report
7/12reports followed by a rise
ReportEPS vs estimateRevenue vs estimateStock move
Jul 28, 2026$0.71 vs $0.67+0.8%−6.8%
Apr 28, 2026$0.57 vs $0.58−0.3%+0.6%
Jan 27, 2026$0.62 vs $0.58+0.4%−3.8%
Oct 28, 2025$0.61 vs $0.45+0.9%+2.7%
Jul 22, 2025$0.36 vs $0.41+0.2%+6.1%
Apr 22, 2025$0.44 vs $0.39+0.2%+8.4%
Jan 28, 2025$0.52 vs $0.48+0.6%+7.0%
Oct 22, 2024$0.44 vs $0.43−0.6%−2.9%

Reported earnings per share against the consensus estimate, revenue surprise in percent, and the stock’s price change over the two sessions around the report. How stocks move after earnings

Where IVZ’s revenue comes from

In fiscal 2025 (the year to Dec 31, 2025), IVZ’s largest reported region was Americas, with 74.7% of its $6.4 billion revenue. By region: Americas 74.7%; EMEA, Excluding United Kingdom 20.6%; Asia 4.6%.

By business, the largest segment was Investment Advice, with 72.4% of $6.4 billion revenue (+6.3% on the year before).

  • Americas74.7%
  • EMEA, Excluding United Kingdom20.6%
  • Asia4.6%
SegmentRevenueShareGrowth
Investment Advice$4.6 billion72.4%+6.3%
Distribution and Shareholder Service$1.5 billion23.8%+2.6%
Financial Service, Other$202.2 million3.2%+1.8%
Investment Performance$41.5 million0.7%−10.6%

From IVZ’s annual filings; segment growth compares fiscal 2025 with the year before. Regions are as each company reports them, so one company’s “Asia Pacific” is not another’s. China counts the regions a company reports as China, Greater China or Hong Kong; a separately reported Taiwan is not counted. Which S&P 500 companies depend most on China?

Members of Congress who traded IVZ

As of Oct 20, 2026, 12 members of Congress had disclosed 30 trades in IVZ (16 buys and 14 sales) in STOCK Act disclosures filed with the House and Senate. The latest public trade is dated Mar 17, 2026.

Trade dateMemberTypeAmount
Mar 17, 2026Kevin HernSale$15,001–$50,000
Feb 10, 2026Gilbert CisnerosSale$1,001–$15,000
Jan 9, 2026Gilbert CisnerosBuy$1,001–$15,000
Apr 8, 2025Rob BresnahanSale$1,001–$15,000
Oct 17, 2024Gary PetersSale$1,001–$15,000
Nov 3, 2023Ro KhannaBuy$1,001–$15,000
Oct 2, 2023Ro KhannaSale$1,001–$15,000
May 23, 2023Ro KhannaBuy$1,001–$15,000
Aug 23, 2022Ro KhannaSale$1,001–$15,000
Jun 17, 2022Ro KhannaSale$1,001–$15,000

Amounts are the ranges members report, not exact values. The STOCK Act gives members up to 45 days to disclose a trade, so trades appear weeks after they are made. See every member’s disclosed trades

Are IVZ insiders buying or selling?

In the 12 months to Oct 20, 2026, IVZ insiders made no open‑market purchases and no sales worth $11.0 million, according to SEC Form 4 filings. The last open‑market purchase on record was on Oct 2, 2023.

After the 31 insider purchases of $10,000 or more since 2012, IVZ beat the S&P 500 by an average of 2.7 percentage points over the next 12 months; 26% of them were followed by a beat. Across all 17,865 insider purchases in Exent’s study, the average was +17.2% and the median +1.0% against the index.

Q1 ’25
Q2 ’25
Q3 ’25
Q4 ’25
Q1 ’26
Q2 ’26
Q3 ’26
Q4 ’26
DateInsiderRoleValue
Oct 2, 2023Invesco Realty, Inc.10 percent owner$5.0 million
Sep 5, 2023Invesco Realty, Inc.10 percent owner$17.5 million
Jun 14, 2022MM Asset Management Holding LLC10 percent owner$13.4 million
Jun 13, 2022Massachusetts Mutual Life Insurance CoDirector$13.4 million
Jun 13, 2022MM Asset Management Holding LLC10 percent owner$13.3 million

The table lists the latest open‑market purchases on record, leaving out the last 30 days. The chart counts Form 4 purchases and sales by calendar quarter. Purchases are open‑market buys; sales include planned sales under 10b5‑1 trading plans. Do insider buys beat the market?

How much of IVZ is sold short?

As of the Sep 30, 2026 settlement date, 3.67% of IVZ’s float was sold short: 16.1 million shares, or 3.1 days of average trading volume to cover. A year earlier (Oct 15, 2025) it was 3.14%. The median across the 997 US stocks Exent tracks was 4.77%, so IVZ is less heavily shorted than most.

  • Apr 30, 20264.04%
  • May 29, 20264.40%
  • Jun 30, 20264.17%
  • Jul 31, 20263.73%
  • Aug 31, 20262.82%
  • Sep 30, 20263.67%

From FINRA short‑interest reports, filed twice a month; the bars show the short share of the float at each month‑end. Days to cover divides the shares short by the average daily volume. The most shorted stocks

How many institutions own IVZ?

At the end of Q2 2026 (Jun 30, 2026), 697 institutions reported holding IVZ in 13F filings, up 36 from the quarter before and up from 548 a year earlier. Their reported holdings add up to 95.2% of IVZ’s shares. In the quarter 369 institutions added to their positions and 225 cut them.

69713F holders
107new positions
73positions closed
95.2%of shares held by 13F filers

Investment managers with over $100 million in US equities file 13F reports within 45 days of each quarter end, so this is the latest complete quarter. Holdings can add up to more than 100% when shares are lent and counted twice. Which stocks institutions are buying and selling

Is IVZ diluting shareholders?

IVZ’s diluted share count fell 1.9% over the five fiscal years to fiscal 2025 and fell 0.9% in fiscal 2025 alone. Each share now owns a larger slice of the company. The median change across the 1,005 US stocks Exent tracks was −0.1%.

Stock‑based compensation was $80.0 million in fiscal 2025, 1.3% of revenue. IVZ spent $1.9 billion buying back shares, a buyback yield of 12.79% of its market value; stock pay equaled 4.3% of the buybacks.

−0.9%share count, 1 year
−1.9%share count, 5 years
1.3%stock pay as % of revenue
12.79%buyback yield

Weighted‑average diluted shares from IVZ’s annual income statements; stock‑based compensation and buybacks from its cash‑flow statement. Stock dilution and stock‑based compensation, explained

IVZ financial health scores

In Exent’s Oct 20, 2026 snapshot, IVZ’s Piotroski F‑score was 6 out of 9; 62% of scored stocks reach 6 or more. The Altman Z‑score is not meaningful for financial services companies, so it is left out.

The Altman Z‑score combines five balance‑sheet and earnings ratios into one bankruptcy‑risk score: below 1.81 is the distress zone, 1.81–2.99 grey, above 2.99 safe. It is not meaningful for banks, insurers and REITs. The Piotroski F‑score counts nine yes/no tests of profitability, leverage and efficiency; 8–9 is strong, 0–2 weak. Both come from the latest annual statements. Which stocks have the highest bankruptcy risk?

What IVZ talks about on earnings calls

On its latest earnings call (Jul 28, 2026), IVZ’s executives and analysts did not mention AI, against 6 on the call before (Apr 28, 2026); the average across 455 S&P 500 calls that quarter was 12.9. After AI, the most mentioned topic was china (4). Tariffs and recession did not come up.

MentionsJul ’26Apr ’26Jan ’26Oct ’25
AI0600
AI agents0000
Data centers0000
Tariffs0000
China413918
Recession0000
  • AI
    Jul ’26
    0
    Apr ’26
    6
    Jan ’26
    0
    Oct ’25
    0
  • AI agents
    Jul ’26
    0
    Apr ’26
    0
    Jan ’26
    0
    Oct ’25
    0
  • Data centers
    Jul ’26
    0
    Apr ’26
    0
    Jan ’26
    0
    Oct ’25
    0
  • Tariffs
    Jul ’26
    0
    Apr ’26
    0
    Jan ’26
    0
    Oct ’25
    0
  • China
    Jul ’26
    4
    Apr ’26
    13
    Jan ’26
    9
    Oct ’25
    18
  • Recession
    Jul ’26
    0
    Apr ’26
    0
    Jan ’26
    0
    Oct ’25
    0

Word counts in the full transcript of each call, prepared remarks and Q&A, newest first. “AI” also counts generative AI and large language models; “AI agents” counts agentic AI. Which companies talk most about AI?

Which ETFs hold IVZ?

As of Oct 20, 2026, 46 of the 304 ETFs Exent tracks held IVZ. Its largest weight is in DVY (iShares Select Dividend ETF), at 1.14% of the fund.

ETFFundWeight of IVZ
DVYiShares Select Dividend ETF1.14%
DFSVDimensional US Small Cap Value ETF0.69%
DFATDimensional U.S. Targeted Value ETF0.52%
VBRVanguard Small-Cap Value Index Fund ETF Shares0.30%
SCHMSchwab U.S. Mid-Cap ETF0.26%
DFASDimensional U.S. Small Cap ETF0.22%
RSPInvesco S&P 500 Equal Weight ETF0.18%
VBVanguard Small-Cap Index Fund ETF Shares0.17%

Owning several of these funds stacks the same position. How much do VOO, QQQ and VTI overlap?

How much is IVZ’s CEO paid?

Andrew R. Schlossberg, IVZ’s President and Chief Executive Officer, received total pay of $16.3 million for fiscal 2025, up 45.1% from $11.2 million for fiscal 2024, according to the company’s proxy statement filed with the SEC on Apr 2, 2026. 62% of it came as stock and option awards, valued when they were granted rather than when they pay out. The median CEO pay across the 378 S&P 500 companies Exent tracks was $17.2 million, so IVZ’s CEO earned less than most.

Pay componentAmountShare of total
Salary$750,0004.6%
Stock and option awards$10.1 million61.9%
Incentive plan (cash)$5.3 million32.6%
Other$143,6960.9%
Other top executivesRoleTotal pay, 2025
L. Allison DukesSenior Managing Director, Chief Financial Officer$7.1 million
Douglas J. SharpSenior Managing Director, Head of the Americas and EMEA$6.7 million
Andrew T.S. LoSenior Managing Director and Chief Executive Officer, Invesco Asia-Pacific$6.6 million
Tony L. WongSenior Managing Director, Co-Head of Investments$5.9 million

Figures from the summary compensation table of the proxy statement; awards count at their grant‑date value, so one large multi‑year grant can make a single year stand out. CEO pay across the S&P 500

The right benchmark for IVZ

Exent matches every holding to the index with the most similar risk. For IVZ that is MDY. Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read why the S&P 500 is the wrong benchmark for most portfolios.

Other financial services stocks

TickerName5‑year returnVolatility (5y)
BRK-BBerkshire Hathaway Inc.+89.0%17.3%
JPMJPMorgan Chase & Co.+124.6%24.4%
VVisa Inc.+102.8%22.7%
GLGlobe Life Inc.+86.3%42.9%
SEICSEI Investments Company+75.3%22.3%
BMNRBitmine Immersion Technologies, Inc.−70.7%115.5%
CNACNA Financial Corporation+60.0%21.5%
VLYValley National Bancorp+32.5%37.7%

Data and methodology

Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: Exent methodology.

Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Check IVZ with Exent Gems

Wall Street’s average IVZ price target is 20.7% above the latest share price. See what the best‑ranked analysts on IVZ say now in Exent Gems.

  1. Exent ranks Wall Street analysts by their past price‑target hit rate and returns, and keeps the best‑ranked few.
  2. Gems shows who the top‑ranked analysts covering IVZ are, their live calls and the median target of only the top‑rated analysts.
  3. Gems flags the stocks where several top‑ranked analysts agree: a starting point for your own research, not a promise.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

No. IVZ returned +55.4% (+4.5% a year) over the 10 years to Oct 30, 2026, versus +316.3% (+15.3% a year) for the S&P 500, including dividends.

Yes. As of Oct 20, 2026, IVZ (Invesco Ltd.) is one of the 503 stocks in the S&P 500.

IVZ fell −85.3% from peak to trough during the global financial crisis (2007–09), versus −56.5% for the S&P 500.

IVZ fell −57.8% from peak to trough during the covid crash (feb–mar 2020), versus −34.1% for the S&P 500.

IVZ fell −45.0% from peak to trough during the 2022 inflation bear market, versus −25.4% for the S&P 500.

Over the 5 years to Oct 30, 2026, IVZ’s Sharpe ratio was 0.24 and its Sortino ratio 0.39, versus 0.58 and 0.91 for the S&P 500.

IVZ’s 5‑year annualized volatility was 36.4%, higher than the S&P 500’s 17.0%, with a beta of 1.69.

Among large US stocks, the lowest correlations with IVZ over the last 60 months were LLY (−0.05), CRWD (−0.04), PGR (−0.03). Its correlation with long Treasuries (TLT) was 0.43 and with gold (GLD) 0.22.

IVZ beat the consensus earnings-per-share estimate in 8 of its last 12 quarterly reports through Jul 28, 2026, and the revenue estimate in 7 of 12. The stock moved 4.6% on average, up or down, from the close before each report to the close after it.

Andrew R. Schlossberg, IVZ’s President and Chief Executive Officer, received $16.3 million in total pay for fiscal 2025, including a $750,000 salary and $10.1 million in stock and option awards valued at grant, according to the proxy statement filed with the SEC on Apr 2, 2026. The median S&P 500 CEO received $17.2 million.

Yes. As of Oct 20, 2026, 12 members of Congress had disclosed 30 trades in IVZ (16 buys and 14 sales) in STOCK Act disclosures filed with the House and Senate.

As of the Sep 30, 2026 settlement date, 3.67% of IVZ’s float was sold short (16.1 million shares, 3.1 days to cover), according to FINRA short-interest reports. A year earlier it was 3.14%.

No. IVZ’s diluted share count fell 1.9% over the five fiscal years to fiscal 2025 and fell 0.9% in the latest year. Stock-based compensation was 1.3% of revenue, and buybacks totaled $1.9 billion.

What do the best‑ranked analysts say on IVZ now?

Exent ranks Wall Street analysts by their track record. Gems shows who the top‑ranked analysts on IVZ are, their latest calls and the stocks where several of them agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.